Abstract
To determine the antihypertensive efficacy, effect duration and safety of the angiotensin II type 1 receptor blocker candesartan cilexetil and the angiotensin converting enzyme inhibitor enalapril once daily in patients with mild to moderate hypertension. A multicenter, randomised, double-blind parallel group study was performed in Finland, France, the Netherlands, Spain and Sweden. Three-hundred-and-ninety-five men and women in the age range 20-80 years with primary hypertension were randomised to an 8-week double-blind treatment period with either candesartan cilexetil 8-16 mg or enalapril 10-20 mg once daily, with forced dose titration after 4 weeks. Non-invasive ambulatory blood pressure was measured for 36 h at baseline and after 8 weeks. The primary efficacy variable was the change in mean diastolic and systolic ambulatory blood pressure 22-24 h post-dose. There was a significant difference in the adjusted mean difference for the change from baseline to week 8 between candesartan cilexetil and enalapril 22-24 h post-dose by -3.5 mmHg (95% confidence interval, CI: -6.8 to -0.3 mmHg; p < 0.032) in ambulatory systolic blood pressure and -3.0 mmHg (95% CI: -5.1 to -0.8 mmHg; p < 0.008) in ambulatory diastolic blood pressure. ...Continue Reading
References
Oct 1, 1987·The American Journal of Cardiology·S N WillichJ E Muller
Jul 1, 1995·Current Opinion in Nephrology and Hypertension·E ParanR W Schrier
Jul 1, 1996·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·A Overlack
Feb 1, 1997·Journal of Clinical Pharmacology·J BenzM Gatlin
Mar 1, 1997·Journal of Clinical Pharmacology·P ChanY S Lee
Oct 20, 1998·Archives of Internal Medicine·E W van RijnsoeverJ Feenstra
Feb 25, 1999·Lancet·L HanssonJ E Björck
Mar 17, 1999·Journal of Human Hypertension·P S Sever
Citations
Mar 19, 2011·Vascular Health and Risk Management·Gerd BönnerPeter Bramlage
Jan 9, 2010·Vascular Health and Risk Management·Thomas MengdenPeter Bramlage
Aug 19, 2011·Expert Opinion on Drug Safety·Vivencio Barrios, Carlos Escobar
Jun 23, 2005·Current Medical Research and Opinion·Gerd Bönner, Winfried Fuchs
Jun 26, 2007·Current Medical Research and Opinion·Peter A Meredith
Apr 24, 2012·The American Journal of Cardiology·Harikrishna MakaniSripal Bangalore
Mar 18, 2008·Clinical Therapeutics·Ramón C HermidaCarlos Calvo
Nov 23, 2012·Expert Opinion on Pharmacotherapy·Amedeo Mugellini, Valentina Nieswandt
Apr 6, 2005·Hypertension·Timothy W R DoultonGraham A MacGregor
Aug 18, 2006·Cardiovascular Drugs and Therapy·Aldo P Maggioni
Jun 15, 2007·Journal of Hypertension·Maria Jose FabiaJosep Redon
May 16, 2002·Drugs·Stephanie E Easthope, Blair Jarvis
Sep 18, 2007·Expert Review of Cardiovascular Therapy·Vivencio BarriosAlberto Calderon
Sep 1, 2011·Expert Review of Cardiovascular Therapy·Zeeshan Khawaja, Christopher S Wilcox
Nov 30, 2006·PharmacoEconomics·Greg L Plosker, Susan J Keam
Jan 1, 2013·Mass Spectrometry·Toyofumi NakanishiTakayuki Takubo
Feb 6, 2004·Blood Pressure. Supplement·Shigeki YamamotoHiroshi Fujimoto
Dec 7, 2018·Journal of Human Hypertension·Chrisa DimouVasilios Kotsis
Dec 14, 2004·Cardiovascular Drug Reviews·Christoph H GleiterKlaus Mörike